InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,537.02
(
0.51%
)
US TECH 100
19,641.60
(
0.83%
)
Dow Jones
39,308.00
(
-0.06%
)
Brent Oil
86.69
(
-0.26%
)
Bitcoin
58,709.82
(
-2.41%
)
Post# of 19309
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119978
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Pre_Clinical post# 4310

Wednesday, 07/25/2007 3:04:41 AM

Wednesday, July 25, 2007 3:04:41 AM

Post# of 19309
jessellivermore is quite right—GTC will pick its spots judiciously. GTC does not need to go head-to-head with CHO-cell manufacturers will nilly because there are plenty of cases where drugs either can’t be made in CHO cells or can’t be made in CHO cells economically. FVIIa is an example of the latter.

>…the company has stated it plans on entering Phase 1 in 2008 for the CD137 mAb. Got that? Next year they're putting their first mAb in the clinic. mAbs are typically made in CHO cells.<

The CD137 program is an exception. In general, it will not be GTC’s business model to pursue totally new compounds. But you already knew that.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up